Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

August 31, 2011

Conditions
Ovarian Cancer
Interventions
DRUG

Doxil

Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1

DRUG

Avastin

First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression

Trial Locations (3)

10016

New York University Cancer Institute, New York

87106

University of New Mexico, Albuquerque

87505

New Mexico Cancer Care Associates, Santa Fe

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

NYU Langone Health

OTHER

lead

New Mexico Cancer Research Alliance

OTHER